Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gram-Negative Infections
Emblaveo Approved for MDR Gram-Negative Infections
Emblaveo MDR infections pose a growing threat in Portugal, with the public assessment report evaluating Emblaveo (aztreonam + avibactam) for financing under Decree-Law No. 97/2015. This fixed-dose combination antibiotic targets aerobic Gram-negative microorganisms in adults facing limited options, especially multidrug-resistant (MDR) strains. The pharmacotherapeutic review notes no added therapeutic value over alternatives like ceftazidima + avibactam or ceftolozano + tazobactam, yet recognizes its utility, recommending funding. An economic analysis, including budget impact against meropenem ± colistina, facilitated negotiations for SNS-beneficial terms, with hospital approval on November 11, 2025, under a dedicated contract.
Targeting Metallo-Beta-Lactamase Challenges
The Portuguese public assessment report underscores Emblaveo’s niche against MDR Gram-negative infections amid escalating antimicrobial resistance (AMR). ECDC 2023 data reveal carbapenem resistance at 11.6% in Klebsiella pneumoniae, 14.1% in Pseudomonas aeruginosa, and 10.4% in Acinetobacter spp. in Portugal, highlighting urgent needs for new therapies. Emblaveo pairs aztreonam, a monobactam evading metallo-beta-lactamases (Ambler class B), with avibactam inhibiting classes A, C, and some D beta-lactamases, filling treatment voids. In the REVISIT phase 3 trial with 422 hospitalized adults for complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP), 11.5% of Emblaveo-arm isolates were metallo-beta-lactamase producers versus 13.0% in the meropenem ± colistina arm, with similar susceptibility (67.3% vs. 90.8% for meropenem). These results affirm Emblaveo’s rescue potential for metallo-beta-lactamase strains, especially P. aeruginosa, where colistina’s toxicity limits options. This adds value without superiority in nosocomial high-resistance environments.
Hospital Burden of Resistant Pathogens
MDR Gram-negative infections burden hospitals, as outlined in the report, with nosocomial cases like HAP/VAP (5-20 per 1,000 admissions, 33-50% mortality), cUTIs, and cIAIs often involving Enterobacterales, P. aeruginosa, plus abdominal anaerobes and Staphylococcus aureus. Broad-spectrum beta-lactams with anti-Pseudomonas coverage start empirical therapy, but ESBL and carbapenemase rates drive last-resort needs. ECDC trends and REVISIT baseline data show 18.4% ESBL and 22.6% carbapenemase producers. The 2018-2023 REVISIT trial, multicenter and randomized across 81 sites in 20 countries, compared Emblaveo (n=282, plus metronidazole for cIAI) to meropenem ± colistina (n=140) in intravenous-needing adults, using ITT for 28-day clinical cure. Balanced by infection and APACHE II, groups averaged 55 years old and 66-72% male, with renal dosing like 1,500 mg aztreonam + 500 mg avibactam every 6 hours. These factors validate Emblaveo’s suitability for severe, option-limited Emblaveo MDR infections.
Economic Case for Restricted Reimbursement
Emblaveo’s SNS integration weighs clinical benefits against AMR costs. REVISIT data showed comparable 28-day cure (68.4% Emblaveo vs. 65.7% meropenem; 95% CI -11.4 to 17.8), mortality (4.3% vs. 7.1%), and adverse events (64.4% vs. 63.5%). Budget impact versus meropenem ± colistina shaped confidential terms to ease SNS expenses from ICU stays (28.7% vs. 27.9%) and durations (~8.5-8.9 days). Under Decree-Law 97/2015, approval restricts Emblaveo to in hospital use, promoting stewardship.
